Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PLX Stock Forecast 2026-2027
$2.30
Current Price
$185.31M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PLX Price Targets
+421.7%
To High Target of $12.00
+378.3%
To Median Target of $11.00
+334.8%
To Low Target of $10.00
PLX Price Momentum
0.0%
1 Week Change
-17.6%
1 Month Change
-11.9%
1 Year Change
+27.8%
Year-to-Date Change
-27.9%
From 52W High of $3.19
+74.2%
From 52W Low of $1.32
📊 TOP ANALYST CALLS
Did PLX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Protalix is one of their latest high-conviction picks.
Latest PLX Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, PLX has a bullish consensus with a median price target of $11.00 (ranging from $10.00 to $12.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.30, the median forecast implies a 378.3% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PLX Analyst Ratings
1
Buy
0
Hold
0
Sell
PLX Price Target Range
Low
$10.00
Average
$11.00
High
$12.00
Current: $2.30
Latest PLX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PLX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 19, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 21, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 3, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 14, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 31, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Protalix Biotherapeutics Inc. (PLX) Competitors
The following stocks are similar to Protalix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PLX
Protalix BioTherapeutics
mkt cap
185.31M
Protalix Biotherapeutics Inc. (PLX) Financial Data
Protalix Biotherapeutics Inc. has a market capitalization of $185.31M with a P/E ratio of 26.8x. The company generates $52.74M in trailing twelve-month revenue with a -12.5% profit margin.
Revenue growth is -49.9% quarter-over-quarter, while maintaining an operating margin of -51.1% and return on equity of -14.4%.
Valuation Metrics
Market Cap
$185.31M
Enterprise Value
$169.81M
P/E Ratio
26.8x
PEG Ratio
3.8x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
-49.9%
Gross Margin
+49.4%
Operating Margin
-51.1%
Net Margin
-12.5%
EPS Growth
-49.9%
Financial Health
Cash/Price Ratio
+16.3%
Current Ratio
2.5x
Debt/Equity
17.3x
ROE
-14.4%
ROA
-4.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Protalix Biotherapeutics Inc. (PLX) Business Model
About Protalix Biotherapeutics Inc.
What They Do
Develops therapeutic proteins using plant cell technology.
Business Model
Protalix Biotherapeutics operates a biopharmaceutical model focusing on developing and manufacturing therapeutic proteins through its proprietary plant cell-based expression system. The company generates revenue by collaborating with global pharmaceutical partners to commercialize and distribute its therapies, particularly in the rare diseases sector, where it addresses significant unmet medical needs.
Additional Information
Protalix is notable for its leading product targeting Gaucher disease, showcasing its commitment to innovative treatment options. Based in Israel, the company is positioned within a vibrant biotechnology hub and is dedicated to expanding the therapeutic potential of its platform, contributing to advancements in the biotechnology industry and enhancing patient outcomes for rare genetic conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
226
CEO
Mr. Dror Bashan
Country
United States
IPO Year
1998
Website
www.protalix.comProtalix Biotherapeutics Inc. (PLX) Latest News & Analysis
Latest News
Quick Summary
Protalix BioTherapeutics reported weaker FY25 results but projects FY26 revenue of $78–83 million, driven by Elfabrio's EU approval and strong contributions from Chiesi.
Why It Matters
Protalix's strong FY26 guidance and EU approval for Elfabrio signal potential revenue growth and competitive advantages, which may boost investor confidence and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Protalix Biotherapeutics reported its 2025 financial results, highlighting a new European approval for its Fabry disease therapy and updated guidance for 2026, reflecting significant progress in its pipeline.
Why It Matters
Protalix's new European approval for its Fabry disease therapy and positive 2025 results signal strong growth potential, enhancing investor confidence and interest in future performance.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Protalix BioTherapeutics, Inc. (PLX) held its Q4 2025 earnings call, discussing financial results and company performance. Further details are available in the full transcript.
Why It Matters
Protalix's Q4 2025 earnings reveal financial performance and company outlook, impacting stock valuation and informing investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Protalix BioTherapeutics received EC approval for Elfabrio® dosing, triggering a $25M milestone from Chiesi. Expected cash balance by April 2026 is $50M, with 2026 revenue estimates of $78M-$83M.
Why It Matters
The EC approval of Elfabrio® enhances Protalix's revenue outlook and cash position, while ongoing clinical trials for PRX-115 signal potential for future growth, increasing investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
1 month ago
Quick Summary
Protalix Biotherapeutics received European Commission approval for a new dosing regimen of pegunigalsidase alfa for Fabry disease, triggering a $25 million milestone payment from Chiesi.
Why It Matters
The approval of a new dosing regimen for Protalix's drug can boost patient adherence, potentially increasing sales and market share, while the $25 million milestone payment strengthens cash flow.
Source: Proactive Investors
Market Sentiment:
Positive
Quick Summary
Elfabrio's dosing regimen is not approved in the US; the FDA-approved regimen remains 1mg/kg every 2 weeks. Investors should consider the implications of this regulatory status.
Why It Matters
The unapproved dosing regimen for Elfabrio raises concerns about potential sales and market access in the US, impacting investor confidence and stock performance for related companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PLX Stock
What is Protalix Biotherapeutics Inc.'s (PLX) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Protalix Biotherapeutics Inc. (PLX) has a median price target of $11.00. The highest price target is $12.00 and the lowest is $10.00.
Is PLX stock a good investment in 2026?
According to current analyst ratings, PLX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PLX stock?
Wall Street analysts predict PLX stock could reach $11.00 in the next 12 months. This represents a 378.3% increase from the current price of $2.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Protalix Biotherapeutics Inc.'s business model?
Protalix Biotherapeutics operates a biopharmaceutical model focusing on developing and manufacturing therapeutic proteins through its proprietary plant cell-based expression system. The company generates revenue by collaborating with global pharmaceutical partners to commercialize and distribute its therapies, particularly in the rare diseases sector, where it addresses significant unmet medical needs.
What is the highest forecasted price for PLX Protalix Biotherapeutics Inc.?
The highest price target for PLX is $12.00 from at , which represents a 421.7% increase from the current price of $2.30.
What is the lowest forecasted price for PLX Protalix Biotherapeutics Inc.?
The lowest price target for PLX is $10.00 from at , which represents a 334.8% increase from the current price of $2.30.
What is the overall PLX consensus from analysts for Protalix Biotherapeutics Inc.?
The overall analyst consensus for PLX is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are PLX stock price projections?
Stock price projections, including those for Protalix Biotherapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 10:21 AM UTC